Current Opinion in Lipidology

Papers
(The TQCC of Current Opinion in Lipidology is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Regulation of lipoprotein lipase-mediated lipolysis of triglycerides63
Remnant lipoproteins: are they equal to or more atherogenic than LDL?55
Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease38
Genetic, biochemical, and clinical features of LCAT deficiency: update for 202035
Apolipoprotein C-II: the re-emergence of a forgotten factor32
ANGPTL3 as therapeutic target29
Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency28
The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?28
Mendelian randomization as a tool for causal inference in human nutrition and metabolism27
CD36 (SR-B2) as master regulator of cellular fatty acid homeostasis26
Tangier disease: update for 202026
Very long-chain saturated fatty acids and diabetes and cardiovascular disease25
Hypertriglyceridemia: new approaches in management and treatment25
Impact of ultra-processed food consumption on metabolic health24
Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence23
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia22
Update on apolipoprotein B20
Autosomal recessive hypercholesterolemia: update for 202020
Lipids and peripheral neuropathy19
Management of familial hypercholesterolemia in pregnancy19
Fibroblasts in atherosclerosis: heterogeneous and plastic participants19
Dietary fructose and dyslipidemia: new mechanisms involving apolipoprotein CIII18
Transport of LDLs into the arterial wall: impact in atherosclerosis18
Novel lecithin:cholesterol acyltransferase-based therapeutic approaches18
Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods17
Inborn errors of apolipoprotein A-I metabolism: implications for disease, research and development17
Lipids and brain inflammation in APOE4-associated dementia16
The clinical applicability of polygenic risk scores for LDL-cholesterol: considerations, current evidence and future perspectives16
Small dense low-density lipoprotein particles: clinically relevant?15
Measurement of carotid plaque burden15
The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk15
Dietary treatment to lower cholesterol and triglyceride and reduce cardiovascular risk15
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees14
Evidence for improved survival with treatment of homozygous familial hypercholesterolemia14
Metabolic and cardiovascular outcomes of bariatric surgery14
Depression and cardiovascular disease14
Fatty liver, cardiometabolic disease and mortality14
Apolipoprotein F: a natural inhibitor of cholesteryl ester transfer protein and a key regulator of lipoprotein metabolism13
Extracellular matrix: paving the way to the newest trends in atherosclerosis13
Characteristics of plaque lipid-associated macrophages and their possible roles in the pathogenesis of atherosclerosis13
Homozygous familial hypercholesterolemia: what treatments are on the horizon?13
Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies13
Vascular stiffening and endothelial dysfunction in atherosclerosis13
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease13
Targeting epigenetics as atherosclerosis treatment: an updated view13
Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?13
Familial combined hyperlipidemia is a polygenic trait13
Update on cerebrotendinous xanthomatosis12
Lipid effects of glucagon-like peptide 1 receptor analogs12
Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?11
Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance11
Understanding the ins and outs of lipoprotein (a) metabolism11
The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia11
The iterative lipid impact on inflammation in atherosclerosis11
Angiopoietin-like proteins and postprandial partitioning of fatty acids10
Omega-3 fatty acids and cognitive function10
Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment10
Polygenic risk scores: how much do they add?10
How should low-density lipoprotein cholesterol be calculated in 2022?10
Dyslipidemia and aortic valve disease10
Epigenetics of paraoxonases10
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease10
The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case10
0.023393154144287